Ziyuglycoside I | CAS:35286-58-9 | Manufacturer ChemFaces

Ziyuglycoside I

Citing Use of our Products

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Sent to Email: info@chemfaces.com

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Fax: (0086)-27-84254680
E-mail: manager@chemfaces.com
Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal & Western Union

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $44.7 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Featured Products

Kaempferol 3-O-arabinoside

Catalog No: CFN97572
CAS No: 99882-10-7
Price: $338/5mg

Linderane

Catalog No: CFN98175
CAS No: 13476-25-0
Price: $118/20mg

Tubuloside A

Catalog No: CFN90669
CAS No: 112516-05-9
Price: $/mg

Acteoside

Catalog No: CFN97048
CAS No: 61276-17-3
Price: $60/20mg

3-O-Feruloylquinic acid

Catalog No: CFN92393
CAS No: 1899-29-2
Price: $/mg

Isoliquiritin apioside

Catalog No: CFN90800
CAS No: 120926-46-7
Price: $338/20mg

Rubusoside

Catalog No: CFN90167
CAS No: 64849-39-4
Price: $80/20mg

Description:

Ziyuglycoside I has anti-wrinkle activity, could be used as an active ingredient for cosmetics.

In vitro:

Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11.

Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient.[Pubmed: 18256460]

In order to investigate the potential of a Sanguisorba officinalis root extract as an active ingredient for wrinkle-care cosmetics, we measured its free radical scavenging activity, elastase inhibitory activity, expression of MMP-1 (matrix metalloprotease-1) in vitro, and type I collagen synthesis in normal human fibroblast cells.
METHODS AND RESULTS:
To isolate the main components from the S. officinalis root extract, we purified the extract by solvent fractionation, column chromatography, and recrystallization. The active component was identified as Ziyuglycoside I by a spectroscopic analysis. Ziyuglycoside I increased the expression of type I collagen in a dose-dependent manner (by up to 71.3% at 50 muM). A clinical study of a formulation containing Ziyuglycoside I, which involved visual evaluation and image analysis, showed a significantly different effect (p<0.05) of the test formulation from that of the placebo.
CONCLUSIONS:
This result suggests that Ziyuglycoside I isolated from S. officinalis root extract could be used as an active ingredient for cosmetics.

Int J Mol Sci . 2016 Nov 22;17(11):1903.

Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis[Pubmed: 27879682]

Abstract Background: Due to the aggressive clinical behavior, poor outcome, and lack of effective specific targeted therapies, triple-negative breast cancer (TNBC) has currently been recognized as one of the most malignant types of tumors. In the present study, we investigated the cytotoxic effect of Ziyuglycoside I, one of the major components extracted from Chinese anti-tumor herbal Radix Sanguisorbae, on the TNBC cell line MDA-MB-231. Methods: The underlying molecular mechanism of the cytotoxic effect Ziyuglycoside I on MDA-MB-231 cells was investigated with cell viability assay, flow cytometric analysis and Western blot. Results: Compared to normal mammary gland Hs 578Bst cells, treatment of Ziyuglycoside I resulted in a significant growth inhibitory effect on MDA-MB-231 cells. Ziyuglycoside I induced the G2/M phase arrest and apoptosis of MDA-MB-231 cells in a dose-dependent manner. These effects were found to be partially mediated through the up-regulation of p53 and p21WAF1, elevated Bax/Bcl-2 ratio, and the activation of both intrinsic (mitochondrial-initiated) and extrinsic (Fas/FasL-initiated) apoptotic pathways. Furthermore, the p53 specific siRNA attenuated these effects. Conclusion: Our study suggested that Ziyuglycoside I-triggered MDA-MB-231 cell cycle arrest and apoptosis were probably mediated by p53. This suggests that Ziyuglycoside I might be a potential drug candidate for treating TNBC. Keywords: G2/M phase arrest; MDA-MB-231 cell line; intrinsic and extrinsic apoptosis; Ziyuglycoside I.

Ziyuglycoside I Description

Source:	The roots of Sanguisorba officinalis.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

More...

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089

Structure Identification:

J Sep Sci. 2015 Apr 17.

Development and validation of a quantification method for ziyuglycoside I and II in rat plasma: Application to their pharmacokinetic studies.[Pubmed: 25885584]

This study provided a novel and generally applicable method to determine Ziyuglycoside I and Ziyuglycoside II in rat plasma based on liquid chromatography with tandem mass spectrometry.
METHODS AND RESULTS:
A single step of liquid-liquid extraction with n-butanol was utilized, and ginsenoside Rg3 was chosen as internal standard. Final extracts were analyzed based on liquid chromatography with tandem mass spectrometry. Chromatographic separation was achieved using a Thermo Golden C18 column, and the applied gradient elution program allowed for the simultaneous determination of two ziyuglycosides in a one-step chromatographic separation with a total run time of 10 min. The fully validated methodology for both analytes demonstrated high sensitivity (the lower limit of quantitation was 2.0 ng/mL), good accuracy (% RE ≤ ± 15) and precision (% RSD ≤ 15). The average recoveries of both ziyuglycosides and internal standard were all above 75% and no obvious matrix effect was found. This method was then successfully applied to the preclinical pharmacokinetic studies of Ziyuglycoside I and Ziyuglycoside II.
CONCLUSIONS:
The presently developed methodology would be useful for the preclinical and clinical pharmacokinetic studies for Ziyuglycoside I and Ziyuglycoside II.

CAS No.	35286-58-9	Price	$80 / 20mg
Catalog No.	CFN98464	Purity	>=98%
Molecular Weight	767.0	Type of Compound	Triterpenoids
Formula	C₄₁H₆₆O₁₃	Physical Description	White powder
Download	COA MSDS SDF Manual	Similar structural	Comparison (Web) (SDF)

Product Name	Ziyuglycoside I
CAS No.:	35286-58-9
Catalog No.:	CFN98464
Molecular Formula:	C₄₁H₆₆O₁₃
Molecular Weight:	767.0 g/mol
Purity:	>=98%
Type of Compound:	Triterpenoids
Physical Desc.:	White powder
Source:	The roots of Sanguisorba officinalis.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Price:	$80 / 20mg
Download:	COA MSDS SDF Manual
Similar structural:	Comparison (Web) (SDF)

Size /Price /Stock	10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries	Anti-wrinkle Compound Library Triterpenoids Compound Library

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	1.3038 mL	6.5189 mL	13.0378 mL	26.0756 mL	32.5945 mL
5 mM	0.2608 mL	1.3038 mL	2.6076 mL	5.2151 mL	6.5189 mL
10 mM	0.1304 mL	0.6519 mL	1.3038 mL	2.6076 mL	3.2595 mL
50 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.5215 mL	0.6519 mL
100 mM	0.013 mL	0.0652 mL	0.1304 mL	0.2608 mL	0.3259 mL

CFN95460	Oblonganoside D	943021-91-8	749.0	C₄₁H₆₄O₁₂
CFN91575	Oblonganoside B	943021-89-4	749.0	C₄₁H₆₄O₁₂
CFN95461	3beta-Hydroxyurs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester	434942-42-4	616.8	C₃₆H₅₆O₈
CFN98465	Ziyuglycoside II	35286-59-0	604.8	C₃₅H₅₆O₈
CFN90993	Ilexoside D	109008-27-7	766.97	C₄₁H₆₆O₁₃
CFN92273	Ilexside I	83725-19-3	472.7	C₄₁H₆₆O₁₃
CFN90994	Ilexoside K	109008-26-6	929.10	C₄₇H₇₆O₁₈
CFN97328	Pomolic acid 28-O-beta-D-glucopyranosyl ester	83725-24-0	634.9	C₃₆H₅₈O₉
CFN89311	Kaji-ichigoside F1	95298-47-8	650.85	C₃₆H₅₈O₁₀
CFN89097	Rosamultin	88515-58-6	650.85	C₃₆H₅₈O₁₀